Datar Cancer Genetics Launches Breakthrough Blood Test for Early Detection of 15 Cancers

Early detection of cancer has been the Holy Grail for scientists all over the world. Late stage detection is one of the primary reasons for death in cancer patients. Datar Cancer Genetics has developed a simple non-invasive blood test to detect the presence of cancer in seemingly healthy persons, using advanced molecular analysis of nano particles released by cancer cells. The pattern of various genes expressed in the cancer cells is captured in these nano particles known as ‘exosomes’. This breakthrough technology has been developed in India using latest Artificial Intelligence techniques and is based upon the study of more than 3000 samples from cancer patients. The test analyzes all 22000 protein-coding genes in the human genome and is able to detect the presence of breast, cervices, ovary, endometrium, lung, colon, sarcoma and many more cancers with an accuracy of better than 95%.
The test is available in all cities in India and the company has made arrangements for collection of the blood sample from home/office. The test can be availed by any person above the age of 35 and who has no previous known history of having any cancer.
Speaking at the launch, Dr. D. Akolkar, Director of Research and Innovation said that it is a proud moment not only for the company but also for the country as the test has given a pole vault position in cancer research. He also said that the company, working with a frugal budget has beaten the worldwide competition which is funded with billions of dollars and government support. Dr. Akolkar said that research in cancer is an imperative of recent times and Datar Cancer Genetics has committed significant resources not only for early detection of cancer but towards making the treatment of stage IV patients more effective and possibly curative.
Datar Cancer Genetics Limited has been accredited by NABL and TUV for ISO 9001:2008 for medical reporting and has a modern, differential pressure molecular oncology facility in Nasik, India. With the launch of the Early Warning Test, the company has entered into a USD 20 billion market worldwide.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Merck announces positive event-free survival data from phase 3 KEYNOTE-522 study of Keytruda to treat triple-negative breast cancer